Results 131 to 140 of about 147,268 (335)

Clinical burden and healthcare resource use of congenital thrombotic thrombocytopenic purpura in England: A linked primary and secondary care data analysis

British Journal of Haematology, EarlyView.
Summary Congenital thrombotic thrombocytopenic purpura (cTTP) is an ultra rare haematological disorder. This study aimed to estimate the clinical burden, healthcare resource use (HCRU) and associated costs of cTTP in England using primary and secondary care data. A retrospective cohort study was undertaken using the Clinical Practice Research Datalink (
Erin Barker, Will Lester, Heather Riley, Monica Garrett, Amie Padhiar, Annie Berkley, Sudhakar Manne, Umesh Doobaree, Oliver Heard   +8 more
wiley   +1 more source

Menstrual suppression to decrease intrauterine device expulsion in adolescents with inherited bleeding disorders

International Journal of Gynecology &Obstetrics, Volume 169, Issue 1, Page 421-423, April 2025.
Peter H. Cygan, Kelly M. Kons, Megan H. Fiorillo, Tonya S. Wright   +3 more
wiley   +1 more source

Thrombocytosis and the generation of platelet‐derived microparticles in the pathophysiology of sickle cell disease

British Journal of Haematology, EarlyView.
Thrombocytosis is associated with an increased production of platelet‐derived microparticles from activated platelets, which contribute to vaso‐occlusion in sickle cell disease by perpetuating the cycle of inflammation, procoagulant state and endothelial dysfunction.
Giao N. Lê, Anna Dillon, Owen P. Smith, Corrina McMahon   +3 more
wiley   +1 more source

Non‐canonical PKG1 regulation in cardiovascular health and disease

British Journal of Pharmacology, EarlyView.
It is well established that the cyclic GMP‐dependent protein kinase I (PKG1) is canonically activated by cyclic guanosine monophosphate (cGMP), enabling its regulation of vascular tone, cardiac function and smooth muscle homeostasis. However, diverse non‐canonical stimuli of PKG1 have also been identified.
Jie Su, Joseph Robert Burgoyne
wiley   +1 more source

Structure and Function of a Recombinant von Willebrand Factor Drug Candidate

, 2010
The complex structure, large size, and multiple posttranslational modifications of von Willebrand factor (VWF) presented a technological challenge for the production of recombinant VWF (rVWF).
Ilk, Nicola, Lenting, Peter J., Hanspeter Rottensteiner, Schrenk, Gerald, Sleytr, Uwe B., Ehrlich, Hartmut J., Nicola Ilk, Peter Turecek, Hartmut Ehrlich, Schwarz, Hans Peter, Turecek, Peter L., Varadi, Katalin, Gerald Schrenk, Peter Lenting, Bevers, Edouard, Edouard Bevers, Katalin Varadi, Rottensteiner, Hanspeter, Uwe Sleytr, Hans Schwarz   +19 more
core   +1 more source

Renal‐vascular axis: unmasking its role in vascular endothelial growth factor‐inhibitor vascular toxicity in cancer patients

British Journal of Pharmacology, EarlyView.
Abstract Vascular toxicity is a growing concern in cancer patients receiving vascular endothelial growth factor inhibitor (VEGFi) therapy, posing a significant threat to patient prognosis. While the primary mechanism of VEGFi‐induced vascular toxicity is linked to redox‐sensitive reactions that disrupt vascular tone, leading to hypertension and ...
Grace Whelan, Karla B. Neves
wiley   +1 more source

Prevalence of iron deficiency in patients with mild to moderate bleeding disorders and bleeding disorder of unknown cause

Research and Practice in Thrombosis and Haemostasis
Background: Iron deficiency (ID) and ID anemia (IDA) are often caused by chronic bleeding, especially heavy menstrual bleeding, and thus may occur at a high frequency in patients with mild to moderate bleeding disorders (MBDs).
Tim Dreier, Dino Mehic, Justin Oosterlee, Jasmin Rast, Alexandra Kaider, Helmuth Haslacher, Cihan Ay, Ingrid Pabinger, Johanna Gebhart   +8 more
doaj   +1 more source

Cefotaxime as the potential cause of transient acquired von Willebrand syndrome

, 2006
Acquired von Willebrand syndrome (AvWS) is a relatively rare bleeding disorder. It has been reported in association with myeloproliferative disorders, autoimmune diseases, plasma cell dyscrasias and certain drugs.
Murch, N., N. Murch, Benton, A., M. A. Haj, D. J. Bowen, H. I. Sati, Collins, Peter William, Beddal, A., Bowen, Derrick John, P. Collins, Haj, M. A., Sati, H. I., A. Beddal, A. Benton   +13 more
core   +1 more source

Notoginsenoside‐Fa mitigates vascular endothelial permeability via targeting SUGT1 to stabilize NLRP3 in a resting state

British Journal of Pharmacology, EarlyView.
Background and Purpose Notoginsenoside‐Fa (Noto‐Fa) is an emerging active compound derived from notoginseng with promise in treating cardiovascular diseases. The development of cardiovascular diseases is intricately linked to the damage of vascular endothelium and it is widely acknowledged that numerous chronic inflammation pathways, especially the ...
Xiao‐Ying Yu, Da‐Hao Mai, Xing‐Ming Zhong, Li‐Ting Huang, Lan‐Ting Fu, He‐Cai Wang, Ke Wang, Hai‐Yan Li, Qiu‐He Chen, Yang Chen   +9 more
wiley   +1 more source

Haemostatic changes and bleeding with anti‐IL‐6 directed therapy in autoimmune diseases

British Journal of Pharmacology, EarlyView.
Abstract Anti‐IL‐6 directed therapy, especially tocilizumab (TCZ), is widely used for the treatment of autoimmune diseases such as rheumatoid arthritis, giant cell arteritis and systemic juvenile idiopathic arthritis. Next to being a master regulator of inflammation, IL‐6 also is an important regulator of haemostasis. Although generally well tolerated,
Charlotte D. C. C. van der Heijden, Loes C. Oskam, Lenny van Bon, Chantal P. Rovers   +3 more
wiley   +1 more source